US · Healthcare · Biotechnology
EPS came in at -0.54 against a street estimate of -0.47 — a miss of 14.9%.
Analysts rate Verrica Pharmaceuticals Inc a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $13.83.
| Fund | Stake |
|---|---|
| Caligan Partners LP | 5.38% |
| Cannell Capital LLC | 4.56% |
| Affinity Asset Advisors, LLC | 4.12% |
| Velan Capital Investment Management LP | 2.75% |
| Armistice Capital, LLC | 2.48% |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.63% |
| Vanguard Capital Management, LLC | 1.63% |
| Mariner Wealth Advisors LLC | 1.21% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Verrica Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.